Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guidant gets OK to expand US DES (drug-eluting stent) trial:

This article was originally published in Clinica

Executive Summary

The FDA has given Guidant the green-light to expand enrolment in the US portion of its SPIRIT III drug-eluting stent (DES) trial to the full cohort of 1,292 patients at up to 80 sites. The study is comparing the firm's everolimus-eluting stent, XIENCE V, with the current market-leading DES, Boston Scientific's paclitaxel-eluting stent, Taxus. Results from SPIRIT III will be used to seek FDA approval for XIENCE V for treating coronary artery disease. Guidant initially received conditional investigational device exemption approval to begin the trial with a limited number of sites in May. Some 117 patients have been enrolled in the study to date. XIENCE V comprises as its stent platform Guidant's cobalt chromium Multi-Link Vision system.

You may also be interested in...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts